OCUL
Ocular Therapeutix, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
11.29
▲ 0.20 (1.80%)
MARKET · —
Price
Open
11.20
Prev close
11.09
Day high
11.49
Day low
10.94
Volume
3.02M
Market cap
$2.43B
P/E (TTM)
—
52W range
6.23 – 16.44
Trailing performance
Returnvs SPY
1W
+10.36%
+11.7%
1M
+28.54%
+24.8%
3M
+34.79%
+31.7%
6M
+42.42%
+31.4%
YTD
-8.73%
-21.0%
1Y
-7.36%
-27.4%
3Y
+151.82%
+77.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.43B
Enterprise value$1.91B
Revenue (TTM)$52.05M
Gross profit$-178.16M
EBITDA$-308.46M
Net income$-301.45M
EPS (TTM)$-1.40
Free cash flow$-159.25M
Total cash$598.64M
Total debt$79.38M
Book value / share$2.37
Shares outstanding219.62M
Float184.80M
Short % of float14.37%
Dividend yield—
Beta (5Y)0.94
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.62
PEG ratio—
Price / sales—
Price / book4.68
EV / revenue36.77
EV / EBITDA-6.21
Gross margin0.00%
Operating margin-609.34%
Profit margin0.00%
Return on equity-72.99%
Return on assets-34.95%
Debt / equity15.27
Current ratio13.11
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $51.95M | $63.72M | $58.44M | $51.49M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$265.94M | -$193.51M | -$80.74M | -$71.04M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$265.94M | -$193.51M | -$80.74M | -$71.04M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.39 | -0.35 | +9.4% |
| Mar 2026 | -0.32 | -0.40 | -27.6% |
| Dec 2025 | -0.34 | -0.29 | +13.9% |
| Sep 2025 | -0.35 | -0.38 | -9.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 5 | $14.35M | -1.3% |
| Next quarter | -0.38 | 5 | $14.21M | +7.2% |
| Current year | -1.43 | 4 | $52.93M | +1.9% |
| Next year | -1.45 | 5 | $102.48M | +93.6% |
Analyst targets & ownership
Mean target$27.09
High target$34.00
Low target$18.00
Implied upside139.95%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy4 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders0.93%
Held by institutions95.48%
Institutions holding347
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+924.13K
Net buying
Buy transactions
11
999.15K shares
Sell transactions
10
75.02K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
2.05M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 16, 26 | DUGEL PRAVIN U Chief Executive Officer |
STOCK | 50.09K | $0 | Direct |
| Jun 10, 26 | RAINES MERILEE Director |
STOCK | 14.00K | $0 | Direct |
| Jun 10, 26 | LINDSTROM RICHARD L Director |
STOCK | 14.00K | $0 | Direct |
| Jun 10, 26 | GRAVES ADRIENNE L Director |
STOCK | 14.00K | $0 | Direct |
| Jun 10, 26 | WARDEN CHARLES M Director |
STOCK | 14.00K | $0 | Direct |
| Jun 10, 26 | WILLIAMS LESLIE J. Director |
STOCK | 14.00K | $0 | Direct |
| Jun 10, 26 | HONG SEUNG SUH Director |
STOCK | 14.00K | $0 | Direct |
| Jun 10, 26 | ROBINS JASON SHAND Chief Financial Officer |
STOCK | 15.44K | $0 | Direct |
| Jun 3, 26 | WAHEED NADIA K. Officer |
SELL | 14.83K | $122.63K | Direct |
| May 28, 26 | DUGEL PRAVIN U Chief Executive Officer |
STOCK | 394.70K | $0 | Indirect |
| May 26, 26 | HEIER JEFFREY S. Officer |
SELL | 3.02K | $24.75K | Direct |
| May 26, 26 | DUGEL PRAVIN U Chief Executive Officer |
SELL | 21.16K | $173.48K | Direct |
| May 26, 26 | NAYAK SANJAY Officer |
SELL | 1.86K | $15.24K | Direct |
| May 26, 26 | KAISER PETER KAZUO Officer |
SELL | 2.97K | $24.33K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDERMAN TODD |
Officer | 152.47K | Stock Award(Grant) |
DUGEL PRAVIN U |
Chief Executive Officer | 3.29M | Stock Gift |
HEIER JEFFREY S. |
Officer | 320.35K | Sale |
KAISER PETER KAZUO |
Officer | 266.14K | Sale |
LINDSTROM RICHARD L |
Director | 260.93K | Stock Award(Grant) |
MEYERS STEVE LAWRENCE |
Officer | 217.63K | Stock Award(Grant) |
NAYAK SANJAY |
Officer | 328.80K | Sale |
NOTMAN DONALD D. JR. |
Chief Operating Officer | 366.36K | Sale |
SAROJ NAMRATA |
Officer | 254.62K | Stock Award(Grant) |
WAHEED NADIA K. |
Officer | 300.08K | Sale |
Moving averages & technicals
SMA 10
10.49
+7.60% from price
SMA 20
9.52
+16.36% from price
SMA 50
9.51
+16.52% from price
SMA 100
9.22
+22.45% from price
SMA 200
9.97
+11.14% from price
EMA 12
10.39
+8.69% from price
EMA 26
9.83
+14.82% from price
EMA 50
9.54
+18.29% from price
RSI (14)
66.2
Neutral
MACD (12,26,9)
0.55
Hist 0.25
ATR (14)
0.56
5.09% of price
Realised vol 30D
55.5%
Annualised
Bollinger upper
11.74
20, 2σ
Bollinger lower
7.30
20, 2σ
50 / 200 cross
Death
9.51 vs 9.97
Trend bias
Above 200
+11.14%
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
55.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-57.3%
Peak to trough
Max drawdown 5Y
-82.8%
Peak to trough
ATR 14
0.56
5.09% of price
Beta (reported)
0.94
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.22
Call-heavy session
Put / call open interest
0.86
Positioning, not flow
Max pain
10.00
-9.7% from spot
ATM implied vol
62.3%
Nearest strike to spot
Skew (10% OTM)
-1.2%
Calls bid over puts
Call volume
665
Contracts, this expiry
Put volume
145
Contracts, this expiry
Heaviest call OI
11.00
12.29K contracts
Heaviest put OI
9.00
10.94K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Simply Wall St. · 4h ago
Ocular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI Progress
Simply Wall St. · 12h ago
Ocular Therapeutix (OCUL) Stock Fair Value Edges Higher After Analyst Target Increases
Simply Wall St. · 17h ago
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
StockStory · 23h ago
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
Stocktwits · 5d ago
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
Stocktwits · 5d ago
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 9d ago
Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says
MT Newswires · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.